U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904183) titled 'Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT' on March 25.
Brief Summary: This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (LEN+SIN+DEB-TACE+HAIC) versus lenvatinib plus sintilimab and DEB-TACE (LEN+SIN+DEB-TACE) for large hepatocellular carcinoma (> 7cm) with portal vein tumor thrombosis (PVTT).
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma Non-resectable
Intervention: ...